EMT, CTCs and CSCs in tumor relapse and drug-resistance
Abhisek Mitra(AstraZeneca (Japan)), Shulin Li(The University of Texas MD Anderson Cancer Center)
Cited by 464
Related Papers
Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients
|Scientific Reports|2016|195
FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
|Nature Communications|2019|119
Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
|The Lancet Haematology|2019|82
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
|Nature Reviews Clinical Oncology|2021|58